Cover Image
市場調查報告書

左心室功能障礙 : 開發平台分析

Left Ventricular Dysfunction - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246004
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
左心室功能障礙 : 開發平台分析 Left Ventricular Dysfunction - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 60 Pages
簡介

左心室功能障礙(LVD)或是接著引起的鬱血性心衰竭(CHF)常是造成各種心臟疾病的最終要因。冠狀動脈的堵塞及缺血性心臟疾病佔心臟衰竭原因的大半,同時也常與急性/陳舊性心肌梗塞有關。其他原因還有心肌病和高血壓,以及其他各種要因(瓣膜症,心肌炎等)。這個疾病一般與心臟衰竭和心肌梗塞,其他心血管併發症相關。可以射血分數過低,左心室壁可動性低診斷出。

本報告提供全球各國治療左心室功能障礙用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

左心室功能障礙概要

治療藥的開發

  • 左心室功能障礙開發中產品:概要
  • 左心室功能障礙開發中產品:比較分析

各企業開發中的左心室功能障礙治療藥

大學/研究機關研究中的左心室功能障礙治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

左心室功能障礙治療藥:開發中的產品一覽(各企業)

左心室功能障礙治療藥:研究中的產品一覽(大學/研究機關別)

左心室功能障礙開發治療藥的企業

  • Acorda Therapeutics, Inc.
  • Amgen Inc.
  • Bayer AG
  • Innopharmax Inc.
  • RedHill Biopharma Ltd.
  • TiGenix NV

左心室功能障礙:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • BAY-1142524
  • CAP-1001
  • CAP-1002
  • carvedilol CR
  • carvedilol CR
  • cimaglermin alfa
  • CTX-101
  • omecamtiv mecarbil

左心室功能障礙治療藥:最新開發平台趨勢

左心室功能障礙治療藥:暫停開發的產品

左心室功能障礙治療藥:中止開發的產品

左心室功能障礙相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8257IDB

Summary

Global Markets Direct's, 'Left Ventricular Dysfunction - Pipeline Review, H2 2016', provides an overview of the Left Ventricular Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction
  • The report reviews pipeline therapeutics for Left Ventricular Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Left Ventricular Dysfunction therapeutics and enlists all their major and minor projects
  • The report assesses Left Ventricular Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Left Ventricular Dysfunction Overview
  • Therapeutics Development
    • Pipeline Products for Left Ventricular Dysfunction - Overview
  • Left Ventricular Dysfunction - Therapeutics under Development by Companies
  • Left Ventricular Dysfunction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Left Ventricular Dysfunction - Products under Development by Companies
  • Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Bayer AG
    • Capricor Therapeutics, Inc.
    • Innopharmax Inc.
    • Les Laboratoires Servier SAS
    • Quantum Genomics SA
    • RedHill Biopharma Ltd.
    • TiGenix NV
  • Left Ventricular Dysfunction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BAY-1142524 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAP-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAP-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carvedilol CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carvedilol phosphate CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omecamtiv mecarbil MR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QGC-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-38844 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Left Ventricular Dysfunction - Dormant Projects
  • Left Ventricular Dysfunction - Discontinued Products
  • Left Ventricular Dysfunction - Product Development Milestones
    • Featured News & Press Releases
      • Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013
      • Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013
      • Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Left Ventricular Dysfunction, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Left Ventricular Dysfunction - Pipeline by Amgen Inc., H2 2016
  • Left Ventricular Dysfunction - Pipeline by Bayer AG, H2 2016
  • Left Ventricular Dysfunction - Pipeline by Capricor Therapeutics, Inc., H2 2016
  • Left Ventricular Dysfunction - Pipeline by Innopharmax Inc., H2 2016
  • Left Ventricular Dysfunction - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Left Ventricular Dysfunction - Pipeline by Quantum Genomics SA, H2 2016
  • Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Left Ventricular Dysfunction - Pipeline by TiGenix NV, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Left Ventricular Dysfunction - Dormant Projects, H2 2016
  • Left Ventricular Dysfunction - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Left Ventricular Dysfunction, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top